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Background: It is well known that right coronary artery ostium (RCA-os) is
anatomically different from unprotected left main ostium (ULM-os). However,
there is a little data regarding the comparison of clinical outcome of percutaneous
coronary intervention (PCI) between RCA-os and ULM-os. Therefore, to clarify
the difference of impact between each ostial lesion, clinical outcomes following
PCI between patients who were treated for RCA-os and those for ULM-os were
compared.
Methods: Between January 2004 and December 2011, 1021 consecutive patients
treated for ostial lesions were included in this analysis. After exclusion of patients
treated for both RCA-os and ULM-os, 189 patients with RCA-os and 602 patients
with ULM were enrolled. The study endpoints were major adverse cardiac event
(MACE) during follow up period (median Follow-up 37.4 months) which deﬁned as
target lesion revascularization (TLR), all cause death and MI. Furthermore, the
composite of MACE were evaluated. TLR for ULM-os was considered as treatments
for restenosis of ULM-os itself.
Results: Baseline and procedural characteristics were not signiﬁcantly different be-
tween the 2 groups. The occurrence of MACE was signiﬁcantly higher in the RCA-os
than the ULM-os due to the high rate of TLR (p< 0.001, HR¼6.349, 95%CI 3.980-
10.129). On the contrary, all cause death was signiﬁcantly higher in the ULM-os than
the RCA-os (p¼0.004, HR¼5.627, 95%CI 1.748-18.107).
Conclusions: The TLR rate was signiﬁcantly higher in patients with RCA-os than in
those with ULM-os, while all cause mortality was signiﬁcantly higher in ULM-os
compared to RCAos.
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Background: Treatment of the aorta-ostial (AO) region of the right coronary artery
(RCA) with bare metal stents and ﬁrst-generation drug-eluting stents (DES) has been
associated with a higher risk of target-lesion revascularization (TLR). The aim of the
present analysis was to assess the impact on clinical outcome of RCA ostial stent
coverage with second-generation DES.
Methods: We identiﬁed from the total of 1,391 TWENTE trial patients 321 (23%)
patients with single-vessel RCA treatment. The angiographic data of these patients
were categorized into stenting with AO stent coverage (AOC) versus stenting without
AO stent coverage. A patient was allocated to the AOC group, if any part of the stent
covered the AO region (i.e., within 3 mm of the aortic oriﬁce).
Results: The 67 (20.9%) patients with AOC showed more severe lesion calciﬁca-
tion than the 254 patients without AOC (31.3% vs. 12.6%; p< 0.01). In the AOC
group, there was a higher prevalence of hypercholesterolemia and family history of
coronary disease (75.4% vs. 61.6%, and 68.7% vs. 53.5%, respectively; p¼0.03).
During 2-year follow-up, patients in the AOC group had a higher incidence of TLR
(7.5% vs. 1.6%; p¼0.02). Following adjustment for confounders, AOC indepen-
dently predicted TLR with an adjusted hazard ratio of 4.1 (95%CI: 1.17-15.48;
p¼0.04).
Conclusions: Treatment of the AO region of the RCA with second-generation DES is
feasible, but our data suggest that stent coverage of the right AO segment remains a
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Coronary Intervention for Patients with Diabetes Mellitus - Can Newer
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Background: Coronary artery bypass graft surgery (CABG) compared with percu-
taneous coronary intervention (PCI) reduces mortality in diabetics. However, prior
trials compared CABG with balloon angioplasty or older generation stents and it is not
known if the gap between CABG and PCI can be reduced by newer generation drug
eluting stents (DES).
Methods: PUBMED/EMBASE/CENTRAL, search for randomized trials comparing
mode of revascularization in patients with diabetes. Primary outcome was all-cause
mortality. Secondary outcomes were myocardial infarction (MI), repeat revasculari-
zation and stroke. Mixed treatment comparison analyses were performed using a
random effects Poisson regression model.
Results: Seventy-two randomized trials that enrolled 24,742 diabetic patients with a
total of 72,387 patient-years of follow-up satisﬁed our inclusion criteria. When
compared with CABG (reference RR¼ 1.0), PCI with BMS [RR¼1.32(1.01-1.78)],
PES [RR¼1.54 (1.14-2.03)] or SES [RR¼1.40 (1.08-1.88)] were each associated with
an increase in mortality. However, PCI with 2nd generation DES-CoCr EES [RR
¼1.12 (0.67-2.10)] or ZES-R [RR 1.15 (0.28-6.27)] were not associated with a sta-
tistically signiﬁcant increase in mortality. When compared with CABG, there was
excess repeat revascularization with PCI which progressively declined from POBA
(335% increase) to BMS (220% increase) to PES (82% increase) and to SES (47%
increase). However, for PCI with CoCr EES [RR ¼1.32 (0.75-2.24)] and ZES-R [RR
¼2.37 (0.97-5.80)], the excess repeat revascularization was not statistically signiﬁ-
cant, although the point estimate favored CABG. CABG was associated with
numerically higher stroke.
Conclusions: In patients with diabetes, evidence from indirect comparison show
similar mortality between CABG and PCI using 2nd generation DES. CABG was
associated with numerically excess stroke and PCI with 2nd generation DES with
numerically increased repeat revascularization. This hypothesis needs to be tested in
future trials.
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Background: The outcome of patients with diabetes mellitus (DM) after drug-eluting
stent (DES) implantation is worse than that of patients without DM. Pioglitazone (Pio)
decreases cardiovascular (CV) events via anti-atherosclerotic effects, as well as a
blood glucose-lowering effect in patients with DM. We reported that Pio signiﬁcantly
decreased CV events in Japanese patients with DM after DES implantation according
to 1-year follow-up results of the J-DESsERT trial.
Methods: This study aimed to evaluate the effect of Pio on CV events in Japanese
patients with DM after DES implantation based on 3-year follow-up results of the J-
DESsERT trial. In the J-DESsERT trail, a prospective multicenter randomized
controlled trial, 3533 patients were randomized 1:1 to coronary stenting with either a
sirolimus-eluting stent or a paclitaxel-eluting stent, and followed for 3 years. The
criteria of lesion length was  46 mm with vessel diameters from 2.5 to  3.75 mm.
Deﬁnitions for DM in this trial were (1) previous diagnosis of DM; (2) currently on
diabetic medication (oral hypoglycemic drugs or injection of insulin preparation); and
(3) HbA1c6.9%(NGSP) within 30 days before the procedure.
Results: The number of patients with DM was 1705 (48%) in this trial. Among
them, 357 patients had been medicated with Pio before percutaneous coronary
intervention. The rate of CV events (death, myocardial infarction, target vesselronary Lesions - Other B71
